These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3121396)

  • 21. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization.
    Katayama KP; Roesler M; Gunnarson C; Stehlik E; Jagusch S
    J In Vitro Fert Embryo Transf; 1988 Dec; 5(6):332-4. PubMed ID: 3146612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment.
    Brzyski RG; Muasher SJ; Droesch K; Simonetti S; Jones GS; Rosenwaks Z
    Fertil Steril; 1988 Dec; 50(6):917-21. PubMed ID: 3144467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GnRHa flare and IVF pregnancy rates.
    Confino E; Zhang X; Kazer RR
    Int J Gynaecol Obstet; 2004 Apr; 85(1):36-9. PubMed ID: 15050465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
    Cassidenti DL; Sauer MV; Paulson RJ; Ditkoff EC; Rivier J; Yen SS; Lobo RA
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pituitary response to early follicular-phase minidose gonadotropin releasing hormone agonist (GnRHa) therapy: evidence for a second flare.
    Deaton JL; Bauguess P; Huffman CS; Miller KA
    J Assist Reprod Genet; 1996 May; 13(5):390-4. PubMed ID: 8739054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leuprolide acetate for inducing ovulation in women undergoing ovarian stimulation.
    diDonato P; Nola VF; Pittman TV; Marr V; Stubbs C; Meldrum DR
    J Reprod Med; 1995 Oct; 40(10):715-6. PubMed ID: 8551474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate.
    Schoolcraft W; Sinton E; Schlenker T; Huynh D; Hamilton F; Meldrum DR
    Fertil Steril; 1991 Mar; 55(3):563-6. PubMed ID: 1900481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The origin of serum progesterone during the follicular phase of menotropin-stimulated cycles.
    Eldar-Geva T; Margalioth EJ; Brooks B; Algur N; Zylber-Haran E; Diamant YZ
    Hum Reprod; 1998 Jan; 13(1):9-14. PubMed ID: 9512220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization.
    Valbuena D; Pellicer A; Guanes PP; Remohí J; Simón C
    Hum Reprod; 1997 Oct; 12(10):2118-22. PubMed ID: 9402265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme.
    Imoedemhe DA; Chan RC; Sigue AB; Pacpaco EL; Olazo AB
    Hum Reprod; 1991 Sep; 6(8):1088-91. PubMed ID: 1806566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of different regimens of a gonadotropin-releasing hormone analog during ovarian stimulation for in vitro fertilization.
    Benadiva CA; Blasco L; Tureck R; Mastroianni L; Flickinger GL
    Fertil Steril; 1990 Mar; 53(3):479-85. PubMed ID: 2106454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of the use of gonadotropin-releasing hormone analog for triggering ovulation.
    Tulchinsky D; Nash H; Brown K; Paoletti-Falcone V; Polcaro J
    Fertil Steril; 1991 Mar; 55(3):644-6. PubMed ID: 1900489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Lupron screening test: tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization.
    Padilla SL; Smith RD; Garcia JE
    Fertil Steril; 1991 Jul; 56(1):79-83. PubMed ID: 1906020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients.
    Dale PO; Tanbo T; Haug E; Abyholm T
    Hum Reprod; 1992 Sep; 7(8):1085-9. PubMed ID: 1400931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.